Compare GF & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GF | SWKH |
|---|---|---|
| Founded | 1990 | 1996 |
| Country | Germany | United States |
| Employees | N/A | 9 |
| Industry | Investment Managers | Diversified Financial Services |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 198.4M |
| IPO Year | N/A | N/A |
| Metric | GF | SWKH |
|---|---|---|
| Price | $11.47 | $16.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 51.7K | ★ 104.8K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $13.32 |
| 52 Week High | $12.82 | $17.90 |
| Indicator | GF | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 32.19 |
| Support Level | $11.26 | $14.69 |
| Resistance Level | $11.71 | $17.08 |
| Average True Range (ATR) | 0.28 | 0.37 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 31.90 | 12.06 |
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.